ArticleDiagnostics (Basel, Switzerland)2023
A Machine Learning-Based Severity Prediction Tool for the Michigan Neuropathy Screening Instrument.
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Artificial intelligence for detection, prediction, and severity classification of diabetic peripheral neuropathy: a systematic review.BMC medical informatics and decision making · 2026Pooled it
- Machine learning for diabetic foot care: accuracy trends and emerging directions in healthcare AI.Frontiers in public health · 2025Pooled it
- Healthcare workers' knowledge, attitudes, and practices regarding diabetic cardiovascular autonomic neuropathy.Scientific reports · 2025Article
- Association between low-grade inflammation and distal sensorimotor polyneuropathy in type 2 diabetes: a cross-sectional study.BMC neurology · 2025Article
- Metformin Induced Vitamin B12 deficiency: A Cross sectional study. Untangling the connection.Clinical medicine insights. Endocrinology and diabetes · 2025Article
- Enhancing Influenza Detection through Integrative Machine Learning and Nasopharyngeal Metabolomic Profiling: A Comprehensive Study.Diagnostics (Basel, Switzerland) · 2024Article
- Analyzing Diabetes Detection and Classification: A Bibliometric Review (2000-2023).Sensors (Basel, Switzerland) · 2024Review
- Early detection of diabetic neuropathy based on health belief model: a scoping review.Frontiers in endocrinology · 2024Article
- Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN).Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
Abstract
Diabetic sensorimotor polyneuropathy (DSPN) is a serious long-term complication of diabetes, which may lead to foot ulceration and amputation. Among the screening tools for DSPN, the Michigan neuropathy screening instrument (MNSI) is frequently deployed, but it lacks a straightforward rating of severity. A DSPN severity grading system has been built and simulated for the MNSI, utilizing longitudinal data captured over 19 years from the Epidemiology of Diabetes Interventions and Complications (EDIC) trial. Machine learning algorithms were used to establish the MNSI factors and patient outcomes to characterise the features with the best ability to detect DSPN severity. A nomogram based on multivariable logistic regression was designed, developed and validated. The extra tree model was applied to identify the top seven ranked MNSI features that identified DSPN, namely vibration perception (R), 10-gm filament, previous diabetic neuropathy, vibration perception (L), presence of callus, deformities and fissure. The nomogram's area under the curve (AUC) was 0.9421 and 0.946 for the internal and external datasets, respectively. The probability of DSPN was predicted from the nomogram and a DSPN severity grading system for MNSI was created using the probability score. An independent dataset was used to validate the model's performance. The patients were divided into four different severity levels, i.e., absent, mild, moderate, and severe, with cut-off values of 10.50, 12.70 and 15.00 for a DSPN probability of less than 50, 75 and 100%, respectively. We provide an easy-to-use, straightforward and reproducible approach to determine prognosis in patients with DSPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.